Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Post-transplant cyclophosphamide based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants

View Full Paper
Ask AI
Bookmark
Share

Authors

RNRajneesh NathPKPooja KhandelwalSSStephen Spellman

Discussion

Loading...

Member takes

Overview

Analysis reveals improved GVHD-free survival in adults with hematologic malignancies receiving post-transplant cyclophosphamide, indicating better prophylaxis strategies.

Key Points

  • GVHD-free survival was significantly higher in the post-transplant cyclophosphamide group compared to CNI/MTX.
  • At 2 years, the post-transplant cyclophosphamide cohort had a GRFS of 41.2% versus lower rates in other groups.
  • Analysis involved over 8,000 adult patients undergoing myeloablative hematopoietic cell transplantation.
  • This study supports post-transplant cyclophosphamide as an effective prophylaxis in adult hematologic malignancy cases.

Cite This Study

Nath et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc9bhttps://doi.org/10.1182/blood-2025-931
View Full Paper
Ask AI
Bookmark
Share